Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilastine psychomotor safety trial in children with allergic rhinitis or urticaria
2018-003940-21Phase 4Completed
- Sponsor
- Faes Farma
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and urticaria comparing Bilastine with Placebo (2 arms). Primary endpoint: Mean change from baseline in mean reaction time on AULA Task X. Started Nov 2018; status: completed.
02
Drugs
bilastine
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)urticaria
Beyond the preview
Go deeper on 2018-003940-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003940-21.